by Laura Kelley – University of Colorado Cancer Center –
Researchers at CU Anschutz Medical Campus have developed ALA-CART, a next-generation therapy aimed at improving outcomes for patients with resistant cancers.
“This next-generation approach, called ALA-CART (adjunctive LAT-activating CAR-T cells), optimizes CAR-T cells to more effectively eliminate cancer cells, including those that have been able to hide from traditional CAR-T cells,” said Catherine Danis, PhD, lead author and postdoctoral fellow at the University of Colorado School of Medicine.
